Zymeworks Stock Price, News & Analysis

Zymeworks Inc. (Nasdaq: ZYME) announced the appointment of Derek J. Miller to its board of directors effective April 10, 2023. Miller brings over 25 years of experience in oncology and corporate development. His expertise is expected to support Zymeworks in its collaboration efforts with Jazz Pharmaceuticals and BeiGene on zanidatamab, a bispecific antibody currently undergoing multiple clinical trials. Kenneth Galbraith, CEO, emphasized Miller's strategic insights will enhance the company's pipeline of drug candidates. Miller's previous roles include leadership positions at Aro Biotherapeutics and Celator Pharmaceuticals, where he contributed to significant collaborations and business strategies that generated substantial revenues. Zymeworks focuses on developing innovative biotherapeutics aimed at improving outcomes for patients with difficult-to-treat cancers.

Zymeworks Inc. (NASDAQ: ZYME), a clinical-stage biotechnology firm, will participate in two upcoming investor conferences. Management will hold one-on-one meetings and present at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25 in Toronto. Additionally, they will participate in the Stifel 2023 Targeted Oncology Days virtually on April 26. Presentations and webcasts will be available on their website. Zymeworks is focused on developing innovative biotherapeutics, including the HER2-targeted bispecific antibody, zanidatamab, currently in various clinical trial phases.

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company, announced eleven abstracts accepted for presentation at the American Association for Cancer Research Annual Meeting from April 14-19, 2023, in Orlando, FL. The abstracts will showcase advancements in the company’s antibody drug conjugates, multispecific antibodies, and clinical candidates, including ZW171 and ZW191. The management team will host a conference call on April 18, 2023, at 6:30 pm EST to discuss these developments. The abstracts reflect Zymeworks' commitment to pioneering treatments for difficult-to-treat cancers.

Zymeworks Inc. (ZYME) reported a significant turnaround in 2022, achieving $412.5 million in total revenue, a sharp increase from $26.7 million in 2021. The company posted a net income of $124.3 million ($1.90 per share) compared to a net loss of $211.8 million in the previous year. Cash resources stand at $492.2 million, ensuring a runway through 2026. Key developments include positive Phase 2 study results for zanidatamab and a substantial licensing agreement with Jazz Pharmaceuticals, potentially worth up to $1.76 billion. Zymeworks aims to advance multiple clinical studies and develop five novel product candidates over the next five years.

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company, announced its participation in two upcoming investor conferences. The management will attend the Barclays Global Healthcare Conference on March 14-15, presenting on March 14 at 10:45 am EST in Miami Beach, FL. Additionally, the team will join the Cantor: The Future of Oncology Virtual Symposium on April 3-4 for virtual meetings and a fireside chat. Presentations and webcasts will be accessible on Zymeworks’ website.

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company, will announce its fourth quarter and full year 2022 financial results on March 7, 2023, after market close. A conference call and webcast will follow at 4:30 p.m. EST to discuss the results and provide a corporate update. Interested parties can access the live webcast and replay on Zymeworks' website. The company focuses on developing multifunctional biotherapeutics for difficult-to-treat cancers, with its lead candidate zanidatamab currently in various clinical trials. Zymeworks aims to make impactful advancements in cancer treatment.

Zymeworks Inc. (Nasdaq: ZYME), a biotechnology firm focused on developing multifunctional biotherapeutics, recently announced its participation in two upcoming investor conferences. The first is the Guggenheim Oncology Conference on February 8-9, featuring one-on-one meetings and a fireside chat on February 9 at 2:10 pm ET in New York, NY. The second is the SVB Securities Global Biopharma Conference on February 14-15, with a presentation scheduled for February 14 at 10:40 am ET. All events will be accessible via Zymeworks’ website.

Jazz Pharmaceuticals and Zymeworks announced results from a Phase 2 trial for zanidatamab, a HER2-targeted bispecific antibody, showcasing compelling efficacy in advanced HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA) patients. The trial revealed an overall confirmed objective response rate (cORR) of 79% and a disease control rate (DCR) of 92%. Notably, the 18-month overall survival (OS) rate was 84%, with median progression-free survival (mPFS) of 12.5 months. The ongoing Phase 3 trial, HERIZON-GEA-01, is expected to provide further data that could support regulatory submissions.

Zymeworks Inc. (Nasdaq: ZYME) has announced key strategic updates and financial guidance for 2023. The company has successfully closed its collaboration with Jazz Pharmaceuticals, marking a significant financial transformation. As of December 31, 2022, Zymeworks reported approximately $490 million in cash resources, with expected cash burn for 2023 between $90 million and $120 million. The company plans to enhance its research and development efforts, with a focus on zanidatamab and zanidatamab zovodotin. Key priorities include advancing multiple clinical trials and establishing additional collaborations.